You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Human Leukocyte Antigen (HLA)

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Ependymoma Trial in Pittsburgh (biological, drug, other)

Recruiting
  • Ependymoma
  • HLA-A2 restricted synthetic tumor antigen
  • +5 more
  • Pittsburgh, Pennsylvania
    Children's Hospital of Pittsburgh of UPMC
Oct 23, 2022

Kidney Transplant Rejection Trial (MDR-102, Immunosuppressive Agents)

Not yet recruiting
  • Kidney Transplant Rejection
  • MDR-102
  • Immunosuppressive Agents
  • (no location specified)
Apr 4, 2022

Hematologic Malignancies Trial in La Jolla (Cyclophosphamide 50 mg/kg IV Days 3 and 4 post transplant)

Suspended
  • Hematologic Malignancies
  • Cyclophosphamide 50 mg/kg IV Days 3 and 4 post transplant
  • La Jolla, California
    UCSD Medical Center
Jul 20, 2022

End Stage Renal Disease Trial in Los Angeles (Tacrolimus Extended-Release Oral Capsule)

Completed
Has Results
  • End Stage Renal Disease
  • Tacrolimus Extended-Release Oral Capsule
  • Los Angeles, California
    Cedars Sinai Medical Center
Jan 7, 2022

Monocyte Expression of Human Leukocyte Antigen - DR Isotype

Recruiting
  • Critical Care
  • Blood sampling
  • Lyon, France
    Service de reanimation chirurgicale
Oct 27, 2022

Immunoglobulins, Plasmapheresis and Rituximab in Lung

Recruiting
  • Lung Transplantation
  • Donor-specific Anti-human Leukocyte Antigen(HLA) Antibodies
  • blood samples
  • Hannover, Germany
    Hannover Medical School, Department of Cardiothoracic, Transplan
Aug 30, 2021

Human Leukocyte Antigen Class II Alleles and Haplotypes

Recruiting
  • Pemphigus
  • +3 more
  • A single blood sample for HLA typing
  • Moscow, Russian Federation
    Sechenov University
Mar 10, 2022

NSCLC, Head and Neck Squamous Cell Carcinoma, Colorectal Carcinoma Trial in Duarte (Autologous, engineered T Cells targeting

Not yet recruiting
  • Non-small Cell Lung Cancer
  • +5 more
  • Autologous, engineered T Cells targeting TP53 R175H
  • Duarte, California
    City of Hope
May 17, 2023

Hematologic Malignancy Trial in New York (melphalan, fludarabine, thiotepa)

Active, not recruiting
  • Hematologic Malignancy
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Jan 21, 2022

Acute Myeloid Leukemia, Myelodysplastic Syndrome Trial in Durham (Idarubicin, Cytarabine, DLI)

Completed
Has Results
  • Acute Myeloid Leukemia
  • Myelodysplastic Syndrome
  • Durham, North Carolina
    Duke University Medical Center
Dec 1, 2020

Human Leukocyte Antigen Typing and Tumor Antigen Expression

Recruiting
  • Refractory Cancer
  • +3 more
    • Chicago, Illinois
    • +3 more
    Feb 14, 2022

    Breast Cancer Trial in Tampa, Boston, New York (PVX-410, Durvalumab, Hiltonol)

    Active, not recruiting
    • Breast Cancer
    • PVX-410
    • +2 more
    • Tampa, Florida
    • +4 more
    May 7, 2021

    Platelet Refractoriness, Hematologic Malignancy Trial in Charlottesville (isatuximab 10 mg/kg)

    Recruiting
    • Platelet Refractoriness
    • Hematologic Malignancy
    • isatuximab 10 mg/kg
    • Charlottesville, Virginia
      University of Virginia
    Jan 27, 2023

    Chronic Kidney Disease (CKD) Trial in New Haven, New York, Philadelphia (REGN5459, REGN5458)

    Not yet recruiting
    • Chronic Kidney Disease (CKD)
    • New York, New York
      New York University Langone Health - Transplant Institute
    Jul 11, 2022

    Will Permit Sites to Proactively Assess TAA, HLA and HPV-16

    Terminated
    • Head and Neck Cancer
    • +7 more
    • Tumor Profiling
    • Scottsdale, Arizona
    • +2 more
    Dec 2, 2022

    Nanoparticle for DSA Removal

    Recruiting
    • Kidney Failure
    • Presence of Donor Specific Antibodies
      • Zurich, ZH, Switzerland
        University Hospital Zurich, Division of Anaesthesiology
      Mar 11, 2022

      Corticosteroids Induced Immunosuppression Using Monocyte Human

      Not yet recruiting
      • Immunosuppression
      • mHLA-DR
      • (no location specified)
      Jan 17, 2022

      Sickle Cell Disease Trial in Atlanta (procedure, drug, other, radiation)

      Recruiting
      • Sickle Cell Disease
      • Bone Marrow Transplant (BMT)
      • +7 more
      • Atlanta, Georgia
        Children's Healthcare of Atlanta
      Sep 13, 2022

      Leukemia, Myeloid, Acute Trial in Canada, United States (VOR33, Mylotarg)

      Recruiting
      • Leukemia, Myeloid, Acute
      • La Jolla, California
      • +8 more
      Jan 31, 2023

      Postoperative Infectious Complications in Colorectal Cancer

      Completed
      • Colorectal Cancer
        • Moscow, Russian Federation
          State Scientific Centre of Coloproctology
        Sep 21, 2021

        Head Neck Cancer, Cervical Cancer, Non-small Cell Carcinoma Trial in Scottsdale, Chapel Hill (TSC-204-A0201, TSC-204-C0702,

        Not yet recruiting
        • Head and Neck Cancer
        • +20 more
        • TSC-204-A0201
        • +4 more
        • Scottsdale, Arizona
        • +1 more
        Aug 3, 2023

        Hematologic Malignancies Trial in Minneapolis (Haplo HCT <55 years old, Haplo HCT =55 years old, GVHD Prophylaxis)

        Recruiting
        • Hematologic Malignancies
        • Haplo HCT <55 years old
        • +4 more
        • Minneapolis, Minnesota
          Masonic Cancer Center at University of Minnesota
        Jan 25, 2023

        Renal Cell Carcinoma, NSCLC, Pancreatic Adenocarcinoma, Colorectal Cancer Trial (RO7515629, tocilizumab)

        Not yet recruiting
        • Renal Cell Carcinoma, Non-small Cell Lung Cancer, Pancreatic Adenocarcinoma, Colorectal Cancer
        • (no location specified)
        Mar 3, 2023

        Antibody-mediated Rejection, Cardiac Transplant Trial in Rochester (Daratumumab and hyaluronidase-fihj)

        Enrolling by invitation
        • Antibody-mediated Rejection
        • Cardiac Transplant
        • Daratumumab and hyaluronidase-fihj
        • Rochester, Minnesota
          Mayo Clinic Rochester
        Apr 11, 2022

        Resected Pancreatic Adenocarcinoma

        Completed
        • Pancreatic Cancer Resectable
        • Multigene panel for next-generation sequencing
        • Shanghai, Shanghai, China
          Ruijin Hospital
        Jul 31, 2022